[go: up one dir, main page]

BR9808100A - Utilização de amandantina para tratamento de hepatite c. - Google Patents

Utilização de amandantina para tratamento de hepatite c.

Info

Publication number
BR9808100A
BR9808100A BR9808100-4A BR9808100A BR9808100A BR 9808100 A BR9808100 A BR 9808100A BR 9808100 A BR9808100 A BR 9808100A BR 9808100 A BR9808100 A BR 9808100A
Authority
BR
Brazil
Prior art keywords
amandantine
treat hepatitis
patients
hepatitis
amantadine
Prior art date
Application number
BR9808100-4A
Other languages
English (en)
Inventor
Jill P Smith
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of BR9808100A publication Critical patent/BR9808100A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DE AMANTADINA PARA TRATAMENTO DE HEPATITE C" São revelados processos para tratamento de pacientes com infecção virótica por meio de agentes farmacêuticos. Em uma concretização o vírus de Hepatite C e o agente farmacêutico são amantadina. Os processos da presente invenção podem ser usados em pacientes que não responderam a ou não podem tolerar tratamento com interferon, bem como pacientes abaixo da idade de dezoito anos.
BR9808100-4A 1997-03-28 1998-03-27 Utilização de amandantina para tratamento de hepatite c. BR9808100A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/826,249 US5849800A (en) 1997-03-28 1997-03-28 Use of amantadine for treatment of Hepatitis C
PCT/US1998/006302 WO1998043625A1 (en) 1997-03-28 1998-03-27 Use of amantadine for treatment of hepatitis c

Publications (1)

Publication Number Publication Date
BR9808100A true BR9808100A (pt) 2000-03-08

Family

ID=25246077

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808100-4A BR9808100A (pt) 1997-03-28 1998-03-27 Utilização de amandantina para tratamento de hepatite c.

Country Status (7)

Country Link
US (1) US5849800A (pt)
EP (1) EP0973510A4 (pt)
JP (1) JP2001521502A (pt)
AU (1) AU7099198A (pt)
BR (1) BR9808100A (pt)
CA (1) CA2285292A1 (pt)
WO (1) WO1998043625A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU746648B2 (en) * 1997-09-18 2002-05-02 F. Hoffmann-La Roche Ag Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6613507B1 (en) 2000-03-21 2003-09-02 Yu-an Chang Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100851861B1 (ko) * 2000-08-07 2008-08-13 사이클론 파아머슈티컬 인코오퍼레이티드 티모신, 인터페론 및 리바비린을 사용한 씨 형 간염의치료
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
JP2006507235A (ja) * 2002-08-01 2006-03-02 フアーマセツト・インコーポレイテツド フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物
KR100626414B1 (ko) 2003-08-27 2006-09-20 선종건 간염 치료용 약제조성물
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
EP2068906B1 (en) 2006-09-19 2012-08-01 Sungkyunkwan University Foundation for Corporate Collaboration Antiviral agent against animal viruses
CN101569617A (zh) * 2009-06-11 2009-11-04 辽宁利锋科技开发有限公司 具有金刚烷结构药物及其衍生物和类似物抗肿瘤新适应症的应用
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3310469A (en) * 1961-08-28 1967-03-21 Du Pont Pharmaceutical compositions and methods utilizing 1-aminoadamantane and its derivatives
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
EP1304335B1 (en) * 1990-04-04 2009-06-10 Novartis Vaccines and Diagnostics, Inc. Hepatitis C virus protease
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
US5428145A (en) * 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
ES2198514T3 (es) * 1991-08-27 2004-02-01 F. Hoffmann-La Roche Ag Cebadores y sondas para la deteccion de la hepatitis c.
EP0532258A2 (en) * 1991-09-09 1993-03-17 Immuno Japan Inc. Oligonucleotides and determination system of HCV genotypes
ZA927837B (en) * 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
US5437974A (en) * 1992-02-04 1995-08-01 Dade International Inc DNA sequence and encoded polypeptide useful in the diagnosis of hepatitis disease
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5552310A (en) * 1992-06-12 1996-09-03 Hiroshi Yoshikura Replication of hepatitis C virus genome and identification of virus having high infectivity
WO1994010981A1 (fr) * 1992-11-18 1994-05-26 Fujisawa Pharmaceutical Co., Ltd. Preparation pharmaceutique a action prolongee
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5599998A (en) * 1994-10-24 1997-02-04 Iowa State University Research Foundation, Inc. Method for the synthesis of adamantane amines
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection

Also Published As

Publication number Publication date
AU7099198A (en) 1998-10-22
WO1998043625A1 (en) 1998-10-08
CA2285292A1 (en) 1998-10-08
JP2001521502A (ja) 2001-11-06
US5849800A (en) 1998-12-15
EP0973510A1 (en) 2000-01-26
EP0973510A4 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
DK0741577T3 (da) Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
BR0306993A (pt) Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ATE73663T1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
BR9106440A (pt) Oligonucleotideo ou analogo de olifonucleotideo e processo para tratar um animal suspeito de ter uma doenca que se caracteriza pela expressao de gene tat de hiv
PT911033E (pt) Utilizacao do interferao de consenso para a reducao dos efeitos secundarios do tratamento com interferoes na hepatite viral
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
ATE481135T1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
BR9804769A (pt) Processo para tratar ou prevenir infecção por pestivìrus em um hospedeiro mamìfero tendo ou sendo suscetìvel a referida infecção,e , para tratar c~elulas de mamìferos em cultura, e, em mamìferos biológicos
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
ATE408340T1 (de) Prävention und behandlung von mycoplasma- assoziierten krankheiten mit trans-sialidase und/oder neuraminidase
BR0212928A (pt) Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento
PT1032402E (pt) Uso de citicolina para o tratamento de esclerose multipla
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
MX9201288A (es) Metodo de tratamiento.
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.